Compare Equinor ASA (EQNR) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs 10X Genomics Inc — how do they compare? Equinor ASA trades at $43.6 (market cap $101.62B), while 10X Genomics Inc trades at $84.56 (market cap $10.07B). The key difference: Equinor ASA is far larger — about 10.1× 10X Genomics Inc's market cap, and Equinor ASA pays a 3.63% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and 10X Genomics Inc for 92 Days on average.
| EQNR | TXG | |
|---|---|---|
Market Cap | $101.62B | $10.07B |
Volume | 4,991,782 | 5,657,286 |
Sector | Energy | Health |
52-Week High | $45.75 | $97.74 |
52-Week Low | $22.41 | $11.48 |
Typical Hold Time | 59 Days | 92 Days |
Enterprise Value | $110.31B | $9.59B |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EQNR trades at $41.61, down 3.26% today, with a bearish technical outlook and mixed fundamental performance. The stock shows attractive valuation metrics including P/E of 11.63 and EV/EBITDA of 2.39, but faces declining profit margins from 19.29% in 2022 to 4.76% in 2025. Recent earnings show two beats and one miss, while analyst consensus remains positive with a $87.50 price target representing significant upside potential from current levels.
The investment case balances deep value characteristics against operational headwinds. While valuation appears compelling with strong cash flows and dividend payments, investors face risks from volatile energy markets and margin compression. The 112% upside to consensus target suggests Wall Street sees substantial recovery potential if operational performance improves.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
